Details of the Drug Combination

General Information of Drug Combination (ID: DCTTL43)

Drug Combination Name

Amonafide Hepzato

Indication

Disease Entry	Status	REF
Invasive ductal carcinoma	Investigative	[1]

Component Drugs

Amonafide DMAH59S

Hepzato DM2AZPP

Small molecular drug

N.A.

High-throughput Screening Result

Testing Cell Line: HS 578T

Zero Interaction Potency (ZIP) Score: 5.52

Bliss Independence Score: 4.37

Loewe Additivity Score: 1.49

LHighest Single Agent (HSA) Score: 3.66

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Adenocarcinoma	DC8B38X	HCT116	Investigative	[4]
Chronic myelogenous leukemia	DC8E8SR	K-562	Investigative	[4]
Carcinoma	DCFACQZ	MCF7	Investigative	[1]
------------------------------------------------------------------------------------

References

1	Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
2	ClinicalTrials.gov (NCT00715637) Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDEStudy. U.S. National Institutes of Health.
3	ClinicalTrials.gov (NCT05022901) An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma. U.S.National Institutes of Health.
4	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.